CSV Validation Remediation: Rebuilding URS Traceability

CSV Validation Remediation: Rebuilding URS Traceability and Risk-Based Testing

Zamann Pharma Support helped a German pharmaceutical company strengthen its computerized system validation (CSV) compliance with EMA and FDA expectations. Instead of the expected minor fixes, we found a systemic issue: validation documents without validation logic.

The URS was incomplete, risk assessment and testing were disconnected, and no one had challenged critical functions under worst-case conditions. In short, the system was “validated” but not defensible.

This reflects a common, dangerous CSV misconception: validation is not document creation, but proof of control. Our team ran a structured assessment and document review, pinpointed the gaps and mapped the path to defensible validation.

Challenges Faced

Incomplete URS: Missing audit trail, interface and ALCOA+ data integrity requirements, with limited sample tracking coverage.
Risk Assessment Disconnected From Testing: Tests lacked risk traceability and verified OQ/PQ coverage of high-risk workflows, omitting interrupted imports, power loss and partial entries.
Fragmented Validation Documentation: Misaligned validation and test plans, an incomplete traceability matrix, and missing links between URS, RA, TM, test scripts and reports.
Happy-Path Testing With Serious Consequences:Testing overlooked key failure scenarios. A nine-hour sync failure affected 46 samples, triggering full PQ re-execution, CAPA and a two-week batch release delay.
Inspection-Readiness Failure: Documentation appeared complete but lacked the evidence needed to withstand EMA or FDA inspection.
Key Validation Warning Signs: Check URS traceability, data integrity, worst-case testing, failed-interface PQ tests and Annex 15 test rationale. Two or more gaps indicate validation risk.

Zamann Pharma Support’s Approach

Structured Assessment and Document Review: First, a structured document review showed the “validated” system could not withstand scrutiny.
Anchoring Validation in Regulatory Expectations: EMA Annex 15 expects risk-based scenarios and 21 CFR 211.63 equipment “fit for intended use.” Likewise, GAMP 5 Second Edition demands lifecycle defensibility, and ICH Q9 testing that mirrors risk.
Rebuild the URS on ALCOA+ and GAMP 5 Principles: Start with a URS built on ALCOA+ and GAMP 5 principles.
Reconnect the URS, RA, TM and Test Protocols: Next, link them so every test traces to a risk and a requirement.
Challenge the System Under Stress: Then, test beyond optimal conditions.
Justify Every Limit and Test Case: This gives protocols the rationale EMA Annex 15 expects.
Make Validation a Logic Chain: Finally, validation becomes a logic chain, not a document set.

Results Achieved

A Clear Verdict: Validated, but Not Defensible: Documents without validation logic meant the “validated” status did not prove control.
Critical Gaps Mapped Across the Validation Chain: Zamann pinpointed gaps in the URS, risk-to-test link and documentation chain.
Inspection Risk Made Visible: The validation could not withstand an EMA or FDA inspection.
A Defined Roadmap to Defensible Validation: The client gained five actions: rebuild the URS, reconnect documents, stress-test, justify limits and test cases, and build a logic chain.
A New Way to See Validation: True validation is not a cost center but a shield. The strongest companies validate confidence, not documents.

Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Contact Us

Need help? Don't hesitate to get in touch

First Name*

Last Name*

Email*

Phone number*

Role*

Department*

Country

Industry

Message

Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

Yes, I agree to receive personalized newsletters with market insights, invitations for exclusive events and educational webinars from the Zamann Pharma Support GmbH.

I consent to the privacy policy and understand that my personal data will be stored and processed*

FAQ

1. How do you build URS-to-test traceability in computerized system validation?

Link the URS to the risk assessment (RA), traceability matrix (TM), test scripts and reports. Every OQ/PQ test should trace to a requirement and its risk, with test plans aligned to the validation plan. Without this chain, CSV may look complete yet fail an EMA or FDA inspection.

2. Which worst-case scenarios should PQ cover for a sample registration workflow?

Beyond correct entries, PQ should cover partial entries, aborted workflows, data errors, interrupted imports, power loss and failed interfaces, per EMA Annex 15 and ICH Q9. In this case, happy-path testing missed a nine-hour sync failure affecting traceability for 46 samples, forcing full PQ re-execution, a CAPA and a two-week batch release delay.

3. What data integrity requirements must a URS define for GMP computerized systems?

A GMP URS should define audit trail requirements, interfacing expectations, ALCOA+ data integrity controls and full sample tracking coverage. If any are missing, Zamann recommends rebuilding it on ALCOA+ and GAMP 5 principles.

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com